GlassScriptPhysician profile
Greg H Savel
NPI 1699751503
$1,925.74
in general payments reported to CMS, 2019-2025
21 companies · $246 in 2025
The $246 reported for 2025 was more than what 80% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $506 · 2021: $430 · 2022: $86.18 · 2023: $197 · 2024: $157 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $332.83 | 2020-2021 | |
| Pfizer INC. | $260.44 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $246.48 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Cranial Technologies, INC | $203.57 | 2019-2025 | Doc Band |
| Corium, LLC | $165.53 | 2021-2025 | Azstarys |
| Tris Pharma INC | $129.47 | 2019-2020 | |
| Adlon Therapeutics L.P. | $93.97 | 2019-2021 | |
| Genentech USA, INC. | $75.89 | 2020-2021 | |
| Sanofi Pasteur INC. | $66.47 | 2019-2024 | |
| Kaleo, INC. | $61.42 | 2019-2023 | Auvi-Q |
| Cipher Pharmaceuticals US LLC | $47.95 | 2025 | Natroba, Spinosad |
| Glaxosmithkline, LLC. | $42.56 | 2020 | |
| Supernus Pharmaceuticals, INC. | $33.69 | 2021-2024 | Qelbree |
| Ironshore Pharmaceuticals INC. | $27.00 | 2024 | |
| Alk-Abello, INC | $22.40 | 2025 | Neffy, Odactra, Grastek |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $21.81 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.11 | 2019 | |
| Shire North American Group INC | $19.77 | 2019 | |
| Collegium Pharmaceutical, INC. | $19.50 | 2025 | Jornay Pm |
| Kowa Pharmaceuticals America, INC. | $18.45 | 2024 | Zoryve |
| Phadia US INC. | $15.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Savel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.